Skip to main content

Merrimack Pharmaceuticals Inc

MACKDelisted May 10, 2024
Industry
Pharmaceutical Preparations
SEC CIK
0001274792

Merrimack Pharmaceuticals Inc was delisted on May 10, 2024; its insiders filed their last Form 4 on Dec 28, 2023; 70 institutions reported holding it in 13F filings for Q1 2024, worth $137.1M in total; no superinvestor held it.

Q2 2021 vs. Q1 2021

How the institutions holding Merrimack Pharmaceuticals Inc changed between Q1 2021 and Q2 2021.

All holders in Q2 2021All holders in Q1 2021

13F holders of MACK: Q1 2021 compared with Q2 2021
MeasureQ1 2021Q2 2021Change
Holders4342−1
Shares7.93M7.87M−61.2K (−0.8%)
Value$49.8M$50.3M+$479.0K (+1.0%)

New holders (5)

Institutions that held Merrimack Pharmaceuticals Inc at the end of Q2 2021 but not at the end of Q1 2021.

Institutions new to MACK in Q2 2021
InstitutionSharesValue% of portfolio
Point72 Asset Management, L.P.209,563$1.34M0.01%
Group One Trading, L.P.34,493$220.0K0.00%
Cetera Advisor Networks LLC13,400$86.0K0.00%
JPMorgan Chase & Co525$3.00K0.00%
Cubist Systematic Strategies, LLC328$2.00K0.00%

Sold out (6)

Institutions that held Merrimack Pharmaceuticals Inc at the end of Q1 2021 and filed for Q2 2021 without it.

Institutions that sold out of MACK in Q2 2021
InstitutionShares, Q1 2021Value, Q1 2021
Voya Financial Advisors, Inc.13,400$85.0K
Wolverine Trading, LLC10,124$64.0K
Mascoma Wealth Management LLC5,000$31.0K
Tower Research Capital LLC (TRC)2,579$16.0K
Barclays PLC320$2.00K
The PNC Financial Services Group, Inc.200$1.00K